All payments made in the preview are in test mode. Read more
Preview
Regulation

FDA clears AI software for coronary CT analysis

Syngo.CT Coronary Cockpit analyzes plaque and supports intervention planning. The clearance applies to the US market.

MedTechPost.com Newsroom
FDA clears AI software for coronary CT analysis
Illustration: AI-generated

Siemens Healthineers reported FDA clearance for Syngo.CT Coronary Cockpit on November 19. The software uses coronary CT angiography data to support coronary artery disease assessment and planning for percutaneous coronary interventions.

Within Syngo.via, AI segments, labels and visualizes coronary plaque. According to the manufacturer, clinicians can assess composition, size and distribution across the coronary tree or individual lesions. The application accepts CCTA data from any CT scanner; Siemens describes additional benefits with its own dual-source and photon-counting systems.

Context and evidence

Image analysis is not a treatment decision. The software supplies information to the clinical team rather than replacing its judgment. The announcement does not provide a direct comparative study showing improved long-term patient outcomes for this new application. Studies of CCTA and photon-counting CT should not be read as isolated proof of its effectiveness.

What it means

Hospitals gain another option for noninvasive coronary analysis. Procurement still depends on integration, local workflows and the applicable regulatory status.

Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.

Author
MedTechPost.com Newsroom
Source-based medical technology reporting with AI assistance and clear editorial context.

More from Regulation